Description
Randomized study that will test the efficacy of lambda interferon to protect front line health care workers from contracting SARS-CoV-2 corona virus which causes COVID-19 disease.
Amendment chain · 3 entries
Each notch is one published row for this agreement: #0 is the original (placed at its start date) and each later notch is an amendment (placed at its amendment date). The height is the agreement's total value as of that row — the source column is cumulative, not a change amount — so the line reads as the commitment over time and the right-most notch is the current commitment shown in the header. For this agreement: $1,000,000 at start, $1,000,000 after amendment #2 (+$0).
- #02020-04-02$1,000,000
- #12020-09-01$1,000,000
- #22021-03-03$1,000,000
| Row | Date | Total value as of row | Change vs previous | Description on this row |
|---|---|---|---|---|
| #0 original | 2020-04-02(start date) | $1,000,000 | — | Randomized study that will test the efficacy of lambda interferon to protect front line health care workers fr… |
| #1 amendment | 2020-09-01 | $1,000,000 | +$0 | Randomized study that will test the efficacy of lambda interferon to protect front line health care workers fr… |
| #2 amendment | 2021-03-03 | $1,000,000 | +$0 | Randomized study that will test the efficacy of lambda interferon to protect front line health care workers fr… |
Related records · 11
Records are related by an explicit link in the data, stated for each group below — never by text similarity. Values are each agreement's current commitment (latest amendment).
Other current agreements for the same recipient (business number 119259505)
| Ref | Department · program | Current value | FY |
|---|---|---|---|
| 172-2025-2026-Q4-1040854 | National Research Council Canada | Conseil national de recherches Canada · Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives | $277,599 | FY2026 |
| 172-2025-2026-Q1-1029941 | National Research Council Canada | Conseil national de recherches Canada · Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives | $328,966 | FY2026 |
| 172-2024-2025-Q3-1023488 | National Research Council Canada | Conseil national de recherches Canada · Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives | $175,702 | FY2025 |
| 271-2024-2025-Q3-00051 | Health Canada | Santé Canada · Substance Use and Addictions Program | $196,656 | FY2025 |
| 271-2025-2026-Q3-00042 | Health Canada | Santé Canada · Substance Use and Addictions Program | $246,656 | FY2025 |
| 172-2023-2024-Q4-1015832 | National Research Council Canada | Conseil national de recherches Canada · Collaborative Science, Technology and Innovation Program – Ideation Fund | $25,000 | FY2024 |
Other recipients funded under "Industrial Research Assistance Program – Contributions to Firms" by National Research Council Canada | Conseil national de recherches Canada (most recent first)
| Ref | Recipient | Fiscal year | Current value | FY |
|---|---|---|---|---|
| 172-2025-2026-Q2-1034675 | Mediphage Bioceuticals, Inc. | FY2027 | $63,380 | FY2027 |
| 172-2025-2026-Q3-1037522 | OBKIO INC. | FY2026 | $50,000 | FY2026 |
| 172-2025-2026-Q3-1037889 | SERVICES DE DEVELOPPEMENT PROFESSIONELS SDP INC | FY2026 | $25,000 | FY2026 |
| 172-2025-2026-Q2-1034040 | Griffith Foods Limited | FY2026 | $54,880 | FY2026 |
| 172-2025-2026-Q3-1037273 | Apollo Machine & Welding Ltd. | FY2026 | $230,000 | FY2026 |
Cite as: Glassbox record view · Federal grants & contributions · 172-2020-2021-Q1-947684 · retrieved 2026-11-14.